Article

12-month results of two ranibizumab trials show promise

The 12-month results of two randomized clinical trials of ranibizumab (Lucentis, Genentech) indicate that the drug shows encouraging signs of activity against vascular endothelial growth factor (VEGF) in age-related macular degeneration (AMD), reported Jeffrey Heier, MD, Friday at the retina subspecialty day at the American Academy of Ophthalmology

Chicago-The 12-month results of two randomized clinical trials of ranibizumab (Lucentis, Genentech) indicate that the drug shows encouraging signs of activity against vascular endothelial growth factor (VEGF) in age-related macular degeneration (AMD), reported Jeffrey Heier, MD, Friday at the retina subspecialty day at the American Academy of Ophthalmology.

The RhuFab V Ocular Treatment Combining the Use of Visudyne to Evaluate Safety Study (FOCUS) is a phase I/II trial of the safety, tolerability, and efficacy of ranibizumab (0.5 mg) combined with photodynamic therapy (PDT) (verteporfin; Visudyne, Novartis/QLT) compared with PDT alone in patients with subfoveal predominantly classic choroidal neovascularization in AMD. All patients received PDT and were then randomized to ranibizumab (0.3 or 0 mg) injections or sham injection for 24 injections over 2 years.

“The 12-month results indicated that over 90% of the patients who received combination therapy reached the primary study endpoint of loss of fewer than 15 letters of visual acuity compared with 68% of patients who received PDT alone,” said Dr. Heier, clinical instructor in ophthalmology, Tuft School of Medicine and Harvard Medical School, Boston.

Importantly, 24% of the patients who received combination therapy had an improvement of three or more lines of vision versus 5% of those who received PDT alone.

The Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular AMD (MARINA) Study is a phase III trial of patients with subfoveal minimally classic/occult choroidal neovascularization secondary to AMD. Patients received either sham injections or ranibizumab (0.3 or 0.5 mg) injections for 24 treatments over 2 years. The 12-month results indicated that “there was a dramatic difference between the ranibizumab patients, 95% of whom lost fewer than 15 letters of vision compared with about 62% of the control patients,” Dr. Heier reported.

“Patients who received ranibizumab were far less likely to loss vision and far more likely to gain vision. There was a low rate of serious ocular adverse events and no apparent safety concerns,” he said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.